Skip to main content
. 2023 May 16;13:1152123. doi: 10.3389/fonc.2023.1152123

Table 2.

Treatments administered in the adjuvant setting (N:270).

Median (range)
Capecitabine cycles 6 (1-8)
N (%)
Radiotherapy
Yes 192 (71.1)
No 53 (19.6)
Unknown 25 (9.3)
Endocrine therapy*
Yes 7 (2.6.)
No 198 (73.3)
Unknown 65 (24.1)

*Administered in patients who had residual disease with a very low expression of only one hormonal receptor.

N, number.